home / stock / vcnx / vcnx news

VCNX News and Press, Vaccinex Inc. From 08/14/20

Stock Information
Company Name: Vaccinex Inc.
Stock Symbol: VCNX
Market: NASDAQ
Website: vaccinex.com
Menu
VCNX VCNX Quote VCNX Short VCNX News VCNX Articles VCNX Message Board
Get VCNX Alerts

News, Short Squeeze, Breakout and More Instantly...
VCNX - Vaccinex EPS beats by $0.12

Vaccinex (NASDAQ: VCNX ) : Q2 GAAP EPS of -$0.39 beats by $0.12 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

VCNX - Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised net proceeds of $19.8 million since June 30 ROCHESTER, N.Y., Aug. ...

VCNX - MVIS, AHT, NIO and CPTA among midday movers

Gainers:  Verona Pharma (NASDAQ: VRNA )   +181% . More news on: Verona Pharma plc, RumbleON, Inc., Checkpoint Therapeutics, Inc., Stocks on the move, , Read more ...

VCNX - NVAX, ERIC among premarket gainers

RumbleON (NASDAQ: RMBL ) +117%  on pilot program with CarGurus. More news on: RumbleON, Inc., Verona Pharma plc, Applied DNA Sciences, Inc., Stocks on the move, , Read more ...

VCNX - ALT, RIGL, BGG and PSV among midday movers

Gainers:  INmune Bio (NASDAQ: INMB ) +114% . More news on: INmune Bio, Inc., Perceptron, Inc., Rigel Pharmaceuticals, Inc., Stocks on the move, , Read more ...

VCNX - Vaccinex adds to rally ahead of expected readout from Huntington's study

Vaccinex ( VCNX +18.3% ) is up again, although 19% off the intraday high of $6.64, adding to its week-long rally after announcing that it remains on track to complete the pivotal Phase 2 SIGNAL study evaluating lead drug pepinemab in Huntington's disease patients on schedule. Shares ha...

VCNX - Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington's Disease

ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, today announced that, notwithstanding the challenges posed by the ongo...
VCNX - Versatile Vaccinex Needs A Trial Or Partner Win, But Scaled Down Operation May Be More Likely

Investment Thesis Vaccinex share price performance since IPO. Source: TradingView . A review of Vaccinex's ( VCNX ) recent share price performance and funding runway might persuade investors to leave this early stage biotech stock well alone, but there is also a case to be made that the s...

VCNX - Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series

Live video moderated discussion with President and CEO, Maurice Zauderer, Ph.D., on Tuesday, June 16, at 10:00 AM ET, immediately followed by an interactive Q&A session ROCHESTER, N.Y., June 09, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology ...

VCNX - Vaccinex EPS beats by $0.30

Vaccinex (NASDAQ: VCNX ): Q1 GAAP EPS of -$0.45 beats by $0.30 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10